Skip to main content
Delfa

← All assets

GV1001

6 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

6

Ongoing

1

Recruiting

0

Completed

4

Sites

41

Countries

9

Endpoints

123

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 123 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
5
Phase 3
1

Trials by status

Not yet recruiting
1
Completed
4
Withdrawn
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
69
Other (unclassified)
31
Function / daily living
9
Behavior / neuropsychiatric
5
Other clinical outcomes
3
Amyloid biomarkers
2
Caregiver / quality of life
2
Disease progression
1
Safety / tolerability / PK
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 26 of 123 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

6

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

5

Neuropsychiatric Inventory (NPI)Behavior

5

ADAS-CogCognition

4

ADCS-Activities of Daily Living (ADCS-ADL)Function

4

Phosphorylated tau 217 (p-tau217)Amyloid

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

6 of 6

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT05189210GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

GV1001

Alzheimer’s disease

Alzheimer's diseasePh 2Completed35Apr 2025-
NCT06235775Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

GV1001

Frontotemporal dementia

Age 41-85Ph 2Completed5Sep 2025-
NCT05819658GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

GV1001

Frontotemporal dementia

Study partner/caregiver requiredPh 2Completed5Oct 2024-results
NCT03184467Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients

GV1001

Alzheimer’s disease

Alzheimer's diseasePh 2Completed1Sep 20192
NCT05303701GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)

GV1001

Alzheimer’s disease

Alzheimer's diseasePh 3Not yet recruiting0Jan 2028-
NCT03959553GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

GV1001

Alzheimer’s disease

Alzheimer's diseasePh 2Withdrawn0Aug 2021-

Showing 1-6 of 6 trials